Navigation Links
diaDexus Preannounces Strong Second Quarter Revenues
Date:6/29/2011

SOUTH SAN FRANCISCO, Calif., June 29, 2011 /PRNewswire/ -- diaDexus, Inc. (OTC Bulletin Board: DDXS), a diagnostics company focused on the development and commercialization of patent-protected in vitro diagnostic products addressing unmet needs in cardiovascular disease, today announced that it expects to report strong revenue growth for the 2011 second quarter with revenues of $3.8 million, a 45% increase over the comparable 2010 quarter.

diaDexus also said it had filed, ahead of plan, a 510(k) application for FDA clearance of a new automated Lp-PLA2 activity assay. FDA clearance will provide an automated Lp-PLA2 assay capable of running on high throughput clinical chemistry analyzers. Measurement of the activity of the Lp-PLA2 enzyme provides different cardiovascular risk assessment information compared to the currently marketed ELISA mass assay which measures the concentration of the enzyme.  A "research-only" version of this activity assay has been used in ongoing Phase 3 trials of GlaxoSmithKline's darapladib, a potential inhibitor of Lp-PLA2.

Finally, diaDexus announced that Patrick Plewman has resigned from his positions of chief executive officer and member of the board of directors. Board member and former VaxGen CEO, James Panek, will serve as Interim CEO. Brian E. Ward, Ph.D., also a member of the Board, will serve as the company's Interim Chief Operating Officer.

Jim Panek commented, "Patrick co-founded diaDexus and led the transformation from research to commercialization of the PLAC Test, the only blood test cleared by the FDA to predict the risk for coronary heart disease and stroke. Patrick leaves at a time of accelerating revenue growth, a second product filed with the FDA and over 2 million cumulative PLAC Tests sold. The company thanks Patrick for his contribution to laying the foundation for continued growth. He will continue to work
'/>"/>

SOURCE diaDexus, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. VaxGen and diaDexus Complete Merger
2. diaDexus, Inc. Adds Two New Directors; Corporate Overview & 3Q Results Webcast Set for November 16, 2010
3. diaDexus, Inc. Reports 2010 Third Quarter Financial Results
4. diaDexus to Present at the Canaccord Genuity Healthcare Conference
5. diaDexus Announces FDA Clearance for New Automated PLAC Test
6. diaDexus, Inc. Reports 2011 First Quarter Financial Results
7. Lpath Demonstrates Strong Safety Profile of Lead Drug Candidate, Sphingomab(TM), in Non-Human Primates
8. AspenBio Pharma Reports Strong Results with Appendicitis Triage Blood Test from Large Multiple Hospital Study
9. Boston Scientific PROMUS(TM) and TAXUS(R) Stents Continue Strong Performance in Safety and Efficacy Measures
10. HealthMedias Strongest Single Quarter Results: Growth Driven by Product Enhancements, New Partnerships
11. SPIRIT III Results Reaffirm Strong Performance of Boston Scientific PROMUS(TM) and TAXUS(R) Express(R) Stents
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... , Sept. 1, 2015  AccuTec Blades, Inc. today ... Industrial Blades division.  EPC announced in May 2015 its ... Verona, Virginia and Obregon, ... the sale process. Rick Gagliano ... AccuTec Blades said, "Our new name, AccuTec Blades, reflects ...
(Date:9/1/2015)... , Sept. 1, 2015 Nevro Corp. ... that is providing innovative evidence-based solutions for the treatment ... submitted its preliminary response to the Patent Trial and ... inter partes review (IPR), filed by a unit ... claims in U.S. Patent No. 8,359,102 (the ,102 patent). The ...
(Date:9/1/2015)... YEHUDA, Israel , Sept. 1, 2015 ... ), a leading innovator of less invasive, miniaturized circulatory ... heart failure, announced today that it has entered into ... . ("Valtech").  Valtech is a privately held company that ... valve repair and replacement devices for the treatment of ...
Breaking Medicine Technology:AccuTec Blades, Inc. Announces Acquisition of Industrial Blades Division from Edgewell Personal Care Company 2Nevro Announces Submission of Preliminary Response to the Patent Trial and Appeals Board 2HeartWare International Enters Into Definitive Agreement To Acquire Valtech Cardio, Ltd. 2HeartWare International Enters Into Definitive Agreement To Acquire Valtech Cardio, Ltd. 3HeartWare International Enters Into Definitive Agreement To Acquire Valtech Cardio, Ltd. 4HeartWare International Enters Into Definitive Agreement To Acquire Valtech Cardio, Ltd. 5HeartWare International Enters Into Definitive Agreement To Acquire Valtech Cardio, Ltd. 6HeartWare International Enters Into Definitive Agreement To Acquire Valtech Cardio, Ltd. 7HeartWare International Enters Into Definitive Agreement To Acquire Valtech Cardio, Ltd. 8HeartWare International Enters Into Definitive Agreement To Acquire Valtech Cardio, Ltd. 9HeartWare International Enters Into Definitive Agreement To Acquire Valtech Cardio, Ltd. 10
... March 30, 2011 Regado Biosciences, a privately held ... control agents, announced that David J. Mazzo, PhD, President ... Company,s 10th Annual Healthcare Conference at the New York ... 6, 2011 at 11:20 a.m. EDT.  The presentation will ...
... Inc. (Nasdaq: ABAX ), a medical products company ... chairman and chief executive officer,  will present at the 10th ... 8:40 a.m. ET. The conference will be held at the ... About Abaxis Abaxis develops, manufactures and markets portable blood ...
Cached Medicine Technology:Regado Biosciences to Present at the Needham & Company's 10th Annual Healthcare Conference in New York City 2Regado Biosciences to Present at the Needham & Company's 10th Annual Healthcare Conference in New York City 3
(Date:9/1/2015)... ... September 01, 2015 , ... Royal River Natural Foods, ... that followed men and women for 19 years and found that, among those who ... take multivitamins. , The report is part of the September 2015 issue of “Natural ...
(Date:9/1/2015)... ... September 01, 2015 , ... ... Nelson, D.O., has joined its medical management team as an Associate Medical Director. ... all sizes and types in the U.S. and abroad. , Dr. Nelson ...
(Date:9/1/2015)... D.C. (PRWEB) , ... September 01, 2015 , ... Two ... better cross cultural relations through food and dining. , Recently named “the next ... and Luigi Diotaiuti are known for telling the whole story behind food and reclaiming ...
(Date:9/1/2015)... ... September 01, 2015 , ... SC&H Group, a leading ... includes being named a “Best of the Best” firm in the U.S., as well ... the “Best of the Best” in the U.S., selected exclusively on performance in specific ...
(Date:9/1/2015)... ... September 01, 2015 , ... ... is now available. With the Connectivity Kit, EasySampler data is automatically ... lab reactor control experiment, on a touchscreen platform. , EasySampler fully automates ...
Breaking Medicine News(10 mins):Health News:New Study Finds Multivitamins Extend Life After Stroke, Retailer Reports 2Health News:Dr. Brent Nelson Joins WorkCare, Inc., as Associate Medical Director 2Health News:Dr. Brent Nelson Joins WorkCare, Inc., as Associate Medical Director 3Health News:Chefs Amy Riolo and Luigi Diotaiuti Embark on Culinary Diplomatic Quest to Build Bridges through Global Cuisine 2Health News:Chefs Amy Riolo and Luigi Diotaiuti Embark on Culinary Diplomatic Quest to Build Bridges through Global Cuisine 3Health News:Chefs Amy Riolo and Luigi Diotaiuti Embark on Culinary Diplomatic Quest to Build Bridges through Global Cuisine 4Health News:SC&H Group Receives Multiple Honors from INSIDE Public Accounting 2Health News:New Technology Allows Unattended Sampling and Synthesis of Chemical Reactions 2Health News:New Technology Allows Unattended Sampling and Synthesis of Chemical Reactions 3
... fibroids, who until now had only an option of a ... of shrinking the fibroid with the drug Mifepristone. Lead researcher ... and vexing problem in women and fibroid relief accounts for ... are symptomatic could have back pain, pain with intercourse, problems ...
... for a long time to its ultraviolet rays, has always been ... German scientists has shown that even moderate sun exposure can result ... skin cancer. Exposure to sun has been shown as the main ... and melanoma, the rarest type of skin cancer, is much weaker. ...
... genetic mutation called C150T transition in people over 100 years ... This genetic mutation was found in the mitochondrial DNA of ... 52 Italian centenarians. The researchers found that 17 per cent ... in only 3.4 per cent of 117 control subjects under ...
... method by which arterial stiffness in elderly hypertensive patients ... is measured by computerized oscillometry at the upper arm. ... Japan studied 42 patients, 26 of whom were over ... and compared it with other methods of evaluating arterial ...
... research project carried out by Juliette van den Dolder at ... can be grown into bone fractures with the help of ... a titanium mesh scaffold into a bone fracture in a ... This resulted in new bone growth being stimulated by the ...
... of same-sex twins in which only one twin had smoked ... theory" that pot can lead to harder drugs. The study ... genetic makeup and all the participants were 30 years of ... teenage drug use. The researchers found that those who were ...
Cached Medicine News:Health News:Treatment for fibroids with "Abortion Pill" 2Health News:Bones repair themselves with bone marrow cells 2
The NexGen CR femoral component is intended for patients who, in the physician's judgement, have good bone stock and whose ligaments provide adequate mediolateral, anteroposterior, and varus/valgus s...
Cruciate retaining, posterior stabilized and constrained components....
The Natural-Knee Family is a complete range of interchangeable, anatomically-designed implants with over 14 years of proven clinical results....
...
Medicine Products: